CStone Pharmaceuticals (SEHK:2616) Loss Swing To C¥270 Million Tests Bullish Growth Narratives

CStone Pharmaceuticals (SEHK:2616) has just posted its FY 2025 first half numbers, with revenue of C¥49.5 million and basic EPS showing a loss of C¥0.21, while trailing 12 month figures sit at C¥269.6 million of revenue and a loss of C¥0.31 in basic EPS. Over recent periods the company has seen revenue move from C¥254.2 million in the first half of 2024 to C¥153.0 million in the second half of 2024 and then to C¥49.5 million in the first half of 2025, with EPS shifting from a profit of C¥0.01 to a loss of C¥0.08 and then a loss of C¥0.21. For investors, these results put the focus squarely on how quickly margins can stabilise given the current loss profile.

See our full analysis for CStone Pharmaceuticals.

With the headline figures on the table, the next step is to compare these results with the prevailing growth and profitability narratives to see which stories hold up and which start to look stretched.

Curious how numbers become stories that shape markets? Explore Community Narratives

Losses Widen To C¥270 Million On Much Lower Revenue

• Net income swung from a C¥15.7 million profit in 1H 2024 to a C¥270.2 million loss in 1H 2025, alongside revenue moving from C¥254.2 million to C¥49.5 million over the same semi annual periods.
• What stands out for the bullish view of strong earnings growth is that the latest trailing 12 month loss of C¥437.0 million and 1H 2025 basic EPS loss of C¥0.21 both sit against forecasts that earnings could grow 90.29% per year. Any optimism has to be weighed against the current loss profile and the sharp shift from the C¥15.7 million profit reported in 1H 2024.

Revenue Run Rate Slows Against 31.2% Growth Story

• On a trailing 12 month basis CStone reports C¥269.6 million of revenue, which contrasts with the step down in period revenue from C¥254.2 million in 1H 2024 to C¥153.0 million in 2H 2024 and then C¥49.5 million in 1H 2025, while the broader forecast still calls for about 31.2% annual revenue growth.
• What is interesting for the bullish argument around faster than market revenue growth is that the 31.2% growth forecast and expectation of a return to profitability within three years sit beside a current trailing 12 month net loss of C¥437.0 million and a move from positive basic EPS of C¥0.01 in 1H 2024 to losses of C¥0.08 in 2H 2024 and C¥0.21 in 1H 2025. The growth story therefore relies on a clear shift from what is visible in the recent semi annual trends.

Curious how these mixed growth and loss trends are being interpreted and turned into market stories right now? Curious how numbers become stories that shape markets? Explore Community Narratives.

Valuation Gap And P/S Multiple Send Mixed Signal

• The current share price of HK$8.33 is described as about 76.1% below a DCF fair value of HK$34.89, while the P/S ratio of 40.2x is lower than the cited 43.7x peer average but above the 13.1x Hong Kong biotech industry average.
• Critics highlight that the company is still unprofitable on a trailing 12 month basis with a C¥437.0 million loss and that shareholders were diluted in the last year. When this is set against a P/S that is cheaper than the peer group but richer than the broader industry, the bearish concern is that the large gap between the HK$8.33 share price and the DCF fair value of HK$34.89 needs to be balanced carefully against both current losses and sector relative valuation risk.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on CStone Pharmaceuticals's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If this mix of risks and potential rewards feels finely balanced, treat it as your cue to move quickly. Review the data yourself and weigh both sides using the 2 key rewards and 1 important warning sign.

See What Else Is Out There

CStone Pharmaceuticals currently reports shrinking period revenue, widening losses and a sharp swing from a C¥15.7 million profit to a C¥270.2 million loss.

If you are uneasy about that level of earnings volatility and loss making, compare it with companies that score well on 284 resilient stocks with low risk scores to find ideas with steadier profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com